Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

From antibody–drug conjugates (ADCs) moving into early-stage disease to arenavirus-based immunotherapies and ctDNA-guided ...

In a recent blog post, the PhRMA industry organisation said that the PDUFA system is "essential to America's edge in drug ...

For decades, contract development and manufacturing organisations (CDMOs) have operated through fragmented models, with drug ...

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying ...

FDA Commissioner Marty Makary has appointed Tracy Beth Høeg as acting director of the Center for Drug Evaluation and Research ...

These days, the phrase “omnichannel engagement” is everywhere. But the way the biopharmaceutical industry thinks about ...

Consistency is another. HCPs are increasingly accustomed to seamless digital experiences in other areas of their professional ...

The federal appeals court has now reversed the 2022 verdict upholding the '039 patent, thereby vacating the Texas court's ...

VTx-002 is described as a first-in-class vectorised antibody targeting molecular pathways involving TAR DNA-binding protein ...

The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

The FDA estimates that a typical non-clinical programme with a monoclonal antibody product could include more than 100 NHPs, ...